TABLE 2.

Patients achieving a reduction^# in the rate of clinically significant exacerbations during the 12-month follow-up period

	Total population¶	Population with one exacerbation or more in the pre-mepolizumab treatment period+
Subjects	368	340
≥50–100% reduction	247 (67)	247 (73)
>0– <50% reduction	52 (14)	52 (15)
No change/increase	66 (18)	40 (12)
Missing§	1 (<1)	1 (<1)

Data are presented as n or n (%). ^#: based on 365 days prior to enrolment plus any exacerbations starting during run-in; ^¶: denominator based on patients with data for historical exacerbations only (n=366); ⁺: denominator based on patients with one historical exacerbation or more only (n=340); patients with zero historical exacerbations were excluded (n=26); ^§: one patient did not have data during the follow-up period and is therefore not included in any of the categories.